Search Result

Results for "

liver injuries model

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Anaplastic lymphoma kinase (ALK) (1) Apical Sodium-Dependent Bile Acid Transporter (4) Apoptosis (5) ASK1 (1) Autophagy (1) Bacterial (4) c-Myc (1) Calcium Channel (1) Caspase (1) COX (1) CXCR (1) Cyclic GMP-AMP Synthase (1) Cytochrome P450 (1) Drug Derivative (1) Endogenous Metabolite (1) Ferroptosis (5) Fungal (3) FXR (1) G Protein-coupled Receptor Kinase (GRK) (1) Galectin (1) GSK-3 (2) HDAC (1) Heme Oxygenase (HO) (1) Histone Acetyltransferase (1) IKK (1) Interleukin Related (5) Isotope-Labeled Compounds (3) JAK (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) mTOR (1) NF-κB (2) Osteopontin (1) p38 MAPK (1) Parasite (2) Phospholipase (1) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) RIP kinase (1) STAT (2) Survivin (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (18) Metabolic Disease (6) Neurological Disease (1)

By Targets:

Akt (1)

Anaplastic lymphoma kinase (ALK) (1)

Apical Sodium-Dependent Bile Acid Transporter (4)

Apoptosis (5)

ASK1 (1)

Autophagy (1)

Bacterial (4)

c-Myc (1)

Calcium Channel (1)

Caspase (1)

COX (1)

CXCR (1)

Cyclic GMP-AMP Synthase (1)

Cytochrome P450 (1)

Drug Derivative (1)

Endogenous Metabolite (1)

Ferroptosis (5)

Fungal (3)

FXR (1)

G Protein-coupled Receptor Kinase (GRK) (1)

Galectin (1)

GSK-3 (2)

HDAC (1)

Heme Oxygenase (HO) (1)

Histone Acetyltransferase (1)

IKK (1)

Interleukin Related (5)

Isotope-Labeled Compounds (3)

JAK (1)

Keap1-Nrf2 (1)

Lactate Dehydrogenase (1)

mTOR (1)

NF-κB (2)

Osteopontin (1)

p38 MAPK (1)

Parasite (2)

Phospholipase (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (1)

RIP kinase (1)

STAT (2)

Survivin (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (18)

Metabolic Disease (6)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-42682

D(+)-Galactosamine hydrochloride 1 Publications Verification D-Galactosamine HCl	Drug Derivative	Inflammation/Immunology
D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-109120

Odevixibat 3 Publications Verification A4250	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-B0149S3

Tranexamic acid-13C2,15N Cyclocapron-¹³C₂,¹⁵N	Isotope-Labeled Compounds	Inflammation/Immunology
Tranexamic acid- ¹³C₂, ¹⁵N (Cyclocapron- ¹³C₂, ¹⁵N) is the ¹³C₂ and ¹⁵N labeled Tranexamic acid. Tranexamic acid is an antifibrinolytic agent that alleviates liver damage and fibrosis in mouse models of chronic bile duct injury .

HY-42682R

D(+)-Galactosamine hydrochloride (Standard) D-Galactosamine HCl (Standard)	Reference Standards	Inflammation/Immunology
D(+)-Galactosamine (hydrochloride) (Standard) is the analytical standard of D(+)-Galactosamine (hydrochloride). This product is intended for research and analytical applications. D(+)-Galactosamine (D-Galactosamine) hydrochloride, which is an established experimental toxin, primarily causes liver injury by the generation of free radicals and depletion of UTP nucleotides. D(+)-Galactosamine hydrochloride intoxication also induces renal dysfunction thus, renal failure is often associated with the end-stage of the liver damage. Lipopolysaccharide/D(+)-Galactosamine-induced acute liver injury is a known animal model of fulminant hepatic failure .

HY-168327

LH10	FXR	Inflammation/Immunology
LH10 is a fexaramine-based agonist for FXR with an EC₅₀ of 0.14 μM. LH10 exhibits liver protection efficacy, ameliorates the alpha naphthylisothiocyanate (ANIT)-induced cholestasis, APAP (HY-66005)-induced acute liver injury and non-alcoholic steatohepatitis (NASH) in mouse models .

HY-169927

Ferroptosis-IN-16	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-16 (Compound 13l) is a specific inhibitor for ferroptosis with an EC₅₀ of 0.7 nM and 0.9 nM in ES-2 cell and LX-2 cell. Ferroptosis-IN-16 ameliorates Acetaminophen (HY-66005)-induced acute liver injury in mouse model, and exhibits good metabolic stability in mouse liver microsomes .

HY-173293

ASK1-IN-8	ASK1	Inflammation/Immunology
ASK1-IN-8 (Compound 35) is an orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with an IC₅₀ value of 1.8 nM . In an experimental mouse model of liver injury induced by Acetaminophen (HY-66005), ASK1-IN-8 can significantly reduce the plasma alanine transaminase (ALT) level, protecting the liver . ASK1-IN-8 can be used in research related to liver diseases .

HY-109120S

Odevixibat-d5 A4250-d₅	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat-d₅ is deuterated labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120R

Odevixibat (Standard)	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Odevixibat (Standard) is the analytical standard of Odevixibat. This product is intended for research and analytical applications. Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-109120S1

Odevixibat-13C6 A4250-¹³C₆	Apical Sodium-Dependent Bile Acid Transporter Isotope-Labeled Compounds	Metabolic Disease
Odevixibat- ¹³C₆ is ¹³C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis .

HY-66005

Acetaminophen Maximum Cited Publications 55 Publications Verification Paracetamol; 4-Acetamidophenol; 4'-Hydroxyacetanilide	COX Histone Acetyltransferase Endogenous Metabolite Bacterial Parasite Ferroptosis	Inflammation/Immunology Cancer
Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC₅₀ of 25.8 μM; is a widely used antipyretic and analgesic agent. . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor . Acetaminophen induces ferroptosis and leads to acute liver injury in mice model .

HY-163897

PROTAC NCOA4 degrader-1	PROTACs Ferroptosis	Inflammation/Immunology
PROTAC NCOA4 degrader-1 (Compound V3) is a PROTAC NCOA4 degrader (DC₅₀: 3 nM in HeLa cells). PROTAC NCOA4 degrader-1 is a ferroptosis inhibitor. PROTAC NCOA4 degrader-1 reduces NCOA4 levels and downregulates intracellular ferrous iron (Fe ²⁺) levels. PROTAC NCOA4 degrader-1 ameliorates liver damage in a CCl₄-induced acute liver injury model. (Red: NCOA4 ligand (HY-149457). Black: linker (HY-163903). Blue: VHL ligand (HY-138678B)) .

HY-170495

HDAC6 degrader-5	HDAC Apoptosis Interleukin Related	Inflammation/Immunology
HDAC6 degrader-5 (Compound 6) exhibits inhibitory and degradation activity against HDAC6, with an IC₅₀ of 4.95 nM and a DC₅₀ of 0.96 nM. HDAC6 degrader-5 inhibits the release of TNF-α, IL-1β and IL-6, blocks the hepatocyte apoptosis. HDAC6 degrader-5 exhibits anti-inflammatory activity in mouse APAP (HY-66005)-induced liver injury models .

HY-N6871

Abietic acid 1 Publications Verification	Bacterial IKK Ferroptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .

HY-121983

CAY10594	Phospholipase Apoptosis GSK-3 Anaplastic lymphoma kinase (ALK) STAT Interleukin Related G Protein-coupled Receptor Kinase (GRK) CXCR Lactate Dehydrogenase	Inflammation/Immunology Cancer
CAY10594 is an orally active PLD2 inhibitor with an IC₅₀ of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis .

HY-N3181

Nodosin	Apoptosis Wnt β-catenin c-Myc Survivin GSK-3 Ferroptosis Keap1-Nrf2 Heme Oxygenase (HO) NF-κB Interleukin Related	Inflammation/Immunology Cancer
Nodosin is an orally active diterpenoid compound that can be isolated from Isodon serra. Nodosin can inhibit the proliferation and induce cell cycle arrest and apoptosis of tumor cells. Nodosin can also inhibit oxidative stress, inflammatory responses, and ferroptosis. Nodosin has anti-inflammatory and anti-tumor activities .

HY-170362

cGAS-IN-4	Cyclic GMP-AMP Synthase	Inflammation/Immunology
cGAS-IN-4 (Compound 36) is an orally active inhibitor for cyclic GMP-AMP synthase (cGAS) with IC₅₀ of 32 nM and 5.8 nM for h-cGAS and m-cGAS. cGAS-IN-4 inhibits the cGAMP in THP-1 cell with an IC₅₀ of 60 nM, which improves the cellular potency. cGAS-IN-4 exhibits anti-inflammatory efficacy in Concanavalin A (HY-P2149)-induced acute liver injury in mouse models . orally active, THP-1, C57Bl/6 mouse, orally active

HY-P990116

Anti-Mouse osteopontin/SPP1 Antibody (103D6)	Osteopontin	Inflammation/Immunology
Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived anti-mouse osteopontin/SPP1 IgG2c κ type antibody inhibitor. Anti-Mouse osteopontin/SPP1 Antibody (103D6) increases cytotoxic T lymphocyte lytic activity and suppresses colon tumor growth. Anti-Mouse osteopontin/SPP1 Antibody (103D6) ameliorates liver injury in common bile duct ligation (CBDL)-induced primary sclerosing cholangitis mice models .

HY-B0885

Econazole 5 Publications Verification (±)-Econazol	Fungal Bacterial Calcium Channel Cytochrome P450	Infection Metabolic Disease
Econazole ((±)-Econazol) is an orally active imidazole antifungal agent, as well as a cytochrome P-450 inhibitor and a blocker of calcium and manganese ion uptake. Econazole is active against a variety of fungi and some Gram-positive bacteria, but has no significant activity against Gram-negative bacteria. Econazole can inhibit the synthesis of prostaglandins and can also induce liver damage .

HY-N6951

Guaiazulene	Apoptosis Akt mTOR Reactive Oxygen Species (ROS) Caspase Bacterial Fungal	Infection Neurological Disease Inflammation/Immunology Cancer
Guaiazulene is a bicyclic sesquiterpene that can cross the blood-brain barrier. Guaiazulene exhibits various biological activities such as anti-inflammatory, antioxidant, hepatoprotective, antibacterial, and anti-tumor properties. Guaiazulene is also commonly used as a colorant in cosmetics. Guaiazulene shows in vitro cytotoxicity to rat neuronal cells and N2a neuroblastoma cells at high concentrations .

HY-173235

Galectin-3-IN-6	Galectin	Cardiovascular Disease Inflammation/Immunology Cancer
Galectin-3-IN-6 (Compound 12) is an orally active inhibitor of galectin-3 (Gal-3), with an IC₅₀ value of 12 nM and a K_d value of 13 nM for Gal-3. In a mouse model of acute liver injury and fibrosis induced by CCl4, Galectin-3-IN-6 can significantly reduce the levels of fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, showing significant anti-fibrotic activity. Galectin-3-IN-6 can be used in the research of fibrotic diseases, cancer, and cardiovascular diseases .

HY-12538

Graveoline Rutamine	Apoptosis Autophagy Fungal Parasite Reactive Oxygen Species (ROS) Interleukin Related JAK STAT	Infection Inflammation/Immunology Cancer
Graveoline (Rutamine) is an orally active alkaloid with various activities such as antifungal, antiparasitic, anti-inflammatory, and antitumor effects. Graveoline can induce tumor cell apoptosis and autophagy through a reactive oxygen species-mediated pathway. Graveoline has an MIC of 500 μg/mL for Candida albicans. Graveoline can be used in the research of various diseases such as tumors and liver injury .

HY-175026

RIPK2-IN-8	RIP kinase NF-κB p38 MAPK Interleukin Related	Inflammation/Immunology
RIPK2-IN-8 is an orally active and highly selective RIPK2 inhibitor (IC₅₀ = 11 nM). RIPK2-IN-8 is highly selective for RIPK2 over RIPK1 (IC₅₀ > 30,000 nM) and has a moderate inhibitory effect on RIPK3 (IC₅₀ = 44.61 nM). RIPK2-IN-8 inhibits the NOD2-RIPK2 signaling pathway and the expression of the inflammatory cytokines IL-6 and TNFα, thereby exerting anti-inflammatory effects. RIPK2-IN-8 has demonstrated anti-inflammatory and hepatoprotective effects in an acute liver injury (ALI) model and can be used in ALI research .

Cat. No.	Product Name	Target	Research Area